{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:34:50Z","timestamp":1793104490042,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T00:00:00Z","timestamp":1411516800000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jacc.2013.05.050","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T05:32:24Z","timestamp":1371101544000},"page":"1154-1162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"title":["Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia"],"prefix":"10.1016","volume":"62","author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo A.","family":"DiCarlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah L.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Margulies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.05.050_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.amjcard.2006.01.066","article-title":"What the statin trials have taught us","volume":"98","author":"Waters","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.05.050_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.05.050_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ahj.2012.10.005","article-title":"Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction","volume":"165","author":"Martin","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.05.050_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ahj.2011.07.013","article-title":"Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease","volume":"162","author":"Virani","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.05.050_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2013.05.050_bib6","unstructured":"Srivastava RA, Hurley TR, Brant AF, et\u00a0al. A novel small molecule, ETC-1002, lowers proatherogenic lipoproteins, reduces adiposity, and improves hepatic steatosis in a hyperlipidemic hamster model (abstr 25085). Presented at: American Heart Association Scientific Sessions 2011; November 12\u201316, 2011; Orlando, FL."},{"key":"10.1016\/j.jacc.2013.05.050_bib7","unstructured":"Hanselman JC, Bradshaw CD, Brant AF, et\u00a0al. ETC-1002 reduces circulating and hepatic triglyceride content and improves glycemic control in KKAy mice (abstr 554). Presented at: ATVB Scientific Sessions 2011; April 28\u201330, 2011; Chicago, IL."},{"key":"10.1016\/j.jacc.2013.05.050_bib8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","article-title":"Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome","volume":"45","author":"Cramer","year":"2004","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2013.05.050_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-2712(18)30645-0","article-title":"The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements","volume":"9","author":"Myers","year":"1989","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacc.2013.05.050_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00769-002-0537-0","article-title":"The College of American Pathologists laboratory accreditation program","volume":"7","author":"Rabinovitch","year":"2002","journal-title":"Accred Qual Assur"},{"key":"10.1016\/j.jacc.2013.05.050_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-2275(20)41577-9","article-title":"A\u00a0comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol","volume":"19","author":"Warnick","year":"1978","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2013.05.050_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of concentration of low density lipoprotein cholesterol in plasma, without using preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2013.05.050_bib13","series-title":"Lipid Research Clinics manual of laboratory operations: lipid and lipoprotein analysis (revised)","year":"1982"},{"key":"10.1016\/j.jacc.2013.05.050_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacc.2013.05.050_bib15","first-page":"e2","article-title":"Heart and stroke statistics\u20142012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.05.050_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.05.050_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighting the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.05.050_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2013.05.050_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.05.050_bib20","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.05.050_bib21","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol lowering statin drugs [press release]. Available at: http:\/\/www.fda.gov\/Drugs\/Drug Safety\/ucm293101.htm. Accessed February 1, 2013."},{"key":"10.1016\/j.jacc.2013.05.050_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1742-1241.2003.tb10508.x","article-title":"Evaluation of the efficacy, safety and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies","volume":"57","author":"Knopp","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacc.2013.05.050_bib23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4065\/76.10.971","article-title":"Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial","volume":"76","author":"Insull","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2013.05.050_bib24","doi-asserted-by":"crossref","first-page":"35U","DOI":"10.1016\/S0002-9149(98)00952-7","article-title":"Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study","volume":"82","author":"Goldberg","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.05.050_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9343(87)90871-0","article-title":"Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia","volume":"83","author":"Knopp","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2013.05.050_bib26","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/sj.ejcn.1600744","article-title":"De novo lipogenesis in humans: metabolic and regulatory aspects","volume":"53","author":"Hellerstein","year":"1999","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacc.2013.05.050_bib27","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.2337\/diacare.26.12.3320","article-title":"Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism","volume":"26","author":"Ascasso","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2013.05.050_bib28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.05.050_bib29","first-page":"99","article-title":"Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels","volume":"3","author":"Dierkes","year":"2001","journal-title":"Vascular Health and Risk Management"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713022560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713022560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:01:55Z","timestamp":1760014915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713022560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0735109713022560"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.05.050","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.05.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}